Moshe Mittelman

Summary

Country: Israel

Publications

  1. ncbi The lower risk MDS patient at risk of rapid progression
    Moshe Mittelman
    Department of Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel
    Leuk Res 34:1551-5. 2010
  2. ncbi [Residency: in the hospital or in the community?]
    Moshe Mittelman
    Department of Medicine Tel Aviv Sourasky Medical Center Sackler Faculty of Medicine, Tel Aviv University
    Harefuah 146:444-6, 501. 2007
  3. ncbi Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines
    Moshe Mittelman
    Department of Medicine, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel
    Isr Med Assoc J 10:374-6. 2008
  4. ncbi Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies
    Moshe Mittelman
    Department of Medicine B and The Hematology Service, Rabin Medical Center Hasharon Hospital, Petah Tikva, Israel
    Eur J Haematol 72:155-65. 2004
  5. ncbi Erythropoietin effects on dendritic cells: potential mediators in its function as an immunomodulator?
    Sara Prutchi Sagiv
    Department of Cell and Developmental Biology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Exp Hematol 36:1682-90. 2008
  6. ncbi Non-erythroid activities of erythropoietin: Functional effects on murine dendritic cells
    Lilach Lifshitz
    Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel
    Mol Immunol 46:713-21. 2009
  7. ncbi Non-erythroid effects of erythropoietin: are neutrophils a target?
    Maayan Avneon
    Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel
    Leuk Res 33:1430-2. 2009
  8. ncbi The implications of anemia in multiple myeloma
    Moshe Mittelman
    Department of Medicine, Rabin Medical Center, Hasharon Hospital, Petah Tikva Sackler School of Medicine, Tel Aviv University, Israel
    Clin Lymphoma 4:S23-9. 2003
  9. ncbi Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models
    Odelia Katz
    Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    J Endocrinol 205:87-95. 2010
  10. ncbi Erythropoietin enhances immune responses in mice
    Odelia Katz
    Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Eur J Immunol 37:1584-93. 2007

Collaborators

Detail Information

Publications26

  1. ncbi The lower risk MDS patient at risk of rapid progression
    Moshe Mittelman
    Department of Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel
    Leuk Res 34:1551-5. 2010
    ..In summary, some patients, classified as "low risk MDS" carry PPF. An appropriate therapeutic approach is indicated. Future updated classifications and prospective trials may lead to a better outcome...
  2. ncbi [Residency: in the hospital or in the community?]
    Moshe Mittelman
    Department of Medicine Tel Aviv Sourasky Medical Center Sackler Faculty of Medicine, Tel Aviv University
    Harefuah 146:444-6, 501. 2007
    ..The influence of such reform on the work in both the hospitals and the community is also discussed. It is notable that Nirel and colleagues should be congratulated for raising this serious question in the national medical debate...
  3. ncbi Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines
    Moshe Mittelman
    Department of Medicine, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel
    Isr Med Assoc J 10:374-6. 2008
  4. ncbi Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies
    Moshe Mittelman
    Department of Medicine B and The Hematology Service, Rabin Medical Center Hasharon Hospital, Petah Tikva, Israel
    Eur J Haematol 72:155-65. 2004
    ..Future trials should determine the role of Epo in myeloma and cancer treatment, besides clarifying concerns about the presence of Epo receptors on some tumor cells...
  5. ncbi Erythropoietin effects on dendritic cells: potential mediators in its function as an immunomodulator?
    Sara Prutchi Sagiv
    Department of Cell and Developmental Biology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Exp Hematol 36:1682-90. 2008
    ..We thus focused on dendritic cells (DCs), the most potent antigen-presenting and T-cell-priming cells, as possible mediators of the immunomodulatory actions of EPO...
  6. ncbi Non-erythroid activities of erythropoietin: Functional effects on murine dendritic cells
    Lilach Lifshitz
    Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel
    Mol Immunol 46:713-21. 2009
    ..Taken together, our data support the premise that DCs are direct targets of EPO, thereby providing an insight to the immunomodulatory functions of EPO...
  7. ncbi Non-erythroid effects of erythropoietin: are neutrophils a target?
    Maayan Avneon
    Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel
    Leuk Res 33:1430-2. 2009
    ..Hence, neutrophils are probably not mediators of the EPO immunological effects, although their counts may be affected by extreme EPO levels...
  8. ncbi The implications of anemia in multiple myeloma
    Moshe Mittelman
    Department of Medicine, Rabin Medical Center, Hasharon Hospital, Petah Tikva Sackler School of Medicine, Tel Aviv University, Israel
    Clin Lymphoma 4:S23-9. 2003
    ..This effect has been shown to be immune mediated. If these exciting data are confirmed in future clinical trials, this may have significant implications on the treatment of MM...
  9. ncbi Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models
    Odelia Katz
    Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    J Endocrinol 205:87-95. 2010
    ..Taken together, our data bear significant clinical implications of EPO treatment in the management of a wide range of metabolic diseases, thus adding an important novel therapeutic potential to this pleiotropic hormone...
  10. ncbi Erythropoietin enhances immune responses in mice
    Odelia Katz
    Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Eur J Immunol 37:1584-93. 2007
    ..Epo-treated mice showed an enhanced immune response also to the clinically relevant hepatitis B surface antigen. These findings suggest a potential novel use of rHuEpo as an immunomodulator...
  11. ncbi Erythropoietin in clinical practice: current use, effect on survival, and future directions
    Howard S Oster
    Department of Internal Medicine A, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Isr Med Assoc J 8:703-6. 2006
    ....
  12. ncbi Erythropoietin induced tumour mass reduction in murine lymphoproliferative models
    Odelia Katz
    Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
    Acta Haematol 114:177-9. 2005
  13. ncbi Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide
    Gideon Y Stein
    Department of Internal Medicine B and the Hematology Unit, Rabin Medical Center, Golda-Hasharon Campus, Petah Tikva, Tel Aviv University, Sackler School of Medicine, Israel
    Int J Hematol 80:94-6. 2004
    ..This novel treatment modality for TTP has been described for only a few patients. A well-controlled clinical trial is warranted to determine the role and place of this therapeutic approach in the management of TTP...
  14. ncbi A prospective national survey of management and clinical outcome of acute myocardial infarction in Israel, 2000
    Solomon Behar
    Israel Center for Disease Control, Gertner Institute, Tel Hashomer, Israel
    Isr Med Assoc J 5:249-54. 2003
    ..Little information is available on the clinical practice and implementation of guidelines for treating acute myocardial infarction patients in Israel...
  15. ncbi Erythropoietin and its receptor: signaling and clinical manifestations
    Jacob Cohen
    Department of Cell Biology and Histology, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel
    Isr Med Assoc J 4:1072-6. 2002
  16. ncbi Platelet function and its clinical significance in the myelodysplastic syndromes
    Aliza Zeidman
    Department of Internal Medicine B, Rabin Medical Center, Golda Hasharon Campus, Petah Tikva, Sackler School of Medicine, Tel Aviv University, Israel
    Hematol J 5:234-8. 2004
    ..In the present study of 23 newly diagnosed MDS patients, PA abnormalities were relatively common, the BTs were usually normal, and bleedings were relatively uncommon and mild at platelet count between 70 and 397 x 109/l...
  17. ncbi The management, early and one year outcome in hospitalized patients with heart failure: a national Heart Failure Survey in Israel--HFSIS 2003
    Moshe Garty
    Recanati Center, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel
    Isr Med Assoc J 9:227-33. 2007
    ..Despite improved management of heart failure patients, their prognosis remains poor...
  18. ncbi Anemia as a risk factor for ischemic heart disease
    Aliza Zeidman
    Department of Medicine B, Rabin Medical Center Golda Hasharon Campus, Petah Tiqva, Israel
    Isr Med Assoc J 6:16-8. 2004
    ..Based on knowledge of the physiologic role of oxygen delivery to the myocardium, anemia may be a cause of more severe cardiovascular diseases or a marker of other processes occurring in the body that induce more severe disease...
  19. ncbi Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
    Bruce D Cheson
    Department of Hematology/Oncology, Georgetown University Hospital, Washington, DC, USA
    Blood 108:419-25. 2006
    ..Because limitations of the IWG criteria have surfaced, based on practical and reported experience, some modifications were warranted. In this report, we present recommendations for revisions of some of the initial criteria...
  20. ncbi Adherence to guidelines for patients hospitalized with heart failure: a nationwide survey
    Alan B Jotkowitz
    Department of Internal Medicine F, Soroka Medical Center and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
    Isr Med Assoc J 8:875-9. 2006
    ..Despite significant advances in the therapy of heart failure, many patients still do not receive optimal treatment...
  21. ncbi Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?
    Sara Prutchi-Sagiv
    Cell and Developmental Biology, Rabin Medical Centre, Golda-Hasharon Campus, Petah-Tikya, Israel
    Br J Haematol 135:660-72. 2006
    ..It is expected that this would boost the immune system, consequently achieving an anti-myeloma function; affecting disease progression and improving the prognosis...
  22. ncbi [Political issues in internal medicine in Europe. A position paper]
    Werner Bauer
    Katedra i Klinika ChorĂ³b Wewnetrznych i Reumatologii Slaskiej Akademii Medycznej, Katowice
    Pol Arch Med Wewn 115:612-6. 2006
    ..Decision-makers in politics and hospitals, insurers, journalists, and the general public need a better understanding of what internal medicine can offer to the health care system and to the individual patient...
  23. ncbi Beyond anaemia management: evolving role of erythropoietin therapy in neurological disorders, multiple myeloma and tumour hypoxia models
    Marc Boogaerts
    University Hospital Gasthuisberg, Leuven, Belgium
    Oncology 69:22-30. 2005
    ..Therefore, the role of epoetin may go well beyond that of increasing haemoglobin levels in anaemic patients, although additional studies are required to confirm these promising results...
  24. ncbi Ocular expression of vascular cell adhesion molecule (VCAM-1) in 2-butoxyethanol-induced hemolysis and thrombosis in female rats
    Abraham Nyska
    Laboratory of Experimental Pathology, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709 9998, USA
    Exp Toxicol Pathol 55:231-6. 2003
    ..No change in ICAM-1 or P-selectin expression was seen. This immunolabeling distribution suggests that VCAM-1 functions in the pathogenesis of BE-related thrombosis by promoting adhesion of erythrocytes to the endothelium...
  25. ncbi A chemically induced rat model of hemolysis with disseminated thrombosis
    Nathan Ezov
    Harlan Biotech Israel Ltd, Rehovot, Israel
    Cardiovasc Toxicol 2:181-94. 2002
    ....
  26. ncbi Late mortality and determinants in patients with heart failure and preserved systolic left ventricular function: the Israel Nationwide Heart Failure Survey
    Basil S Lewis
    Department of Cardiovascular Medicine, Lady Davis Carmel Medical Center, Haifa, Israel
    Isr Med Assoc J 9:234-8. 2007
    ..Heart failure with preserved systolic left ventricular function is a major cause of cardiac disability...